DUBLIN and BUDAPEST, Hungary, Sept. 17, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. announced today that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.

Alexza Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) approved Adasuve ( loxapine ) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.